Xenetic Biosciences (NASDAQ:XBIO) Shares Up 0.8%

Xenetic Biosciences Inc (NASDAQ:XBIOGet Rating) shot up 0.8% on Thursday . The company traded as high as $0.69 and last traded at $0.67. 14,638 shares were traded during trading, a decline of 90% from the average session volume of 152,626 shares. The stock had previously closed at $0.67.

Separately, HC Wainwright reduced their price target on shares of Xenetic Biosciences from $5.00 to $4.00 in a research report on Monday, May 2nd.

The firm’s 50-day moving average is $0.76 and its 200 day moving average is $0.99.

A hedge fund recently bought a new stake in Xenetic Biosciences stock. Steward Partners Investment Advisory LLC purchased a new stake in Xenetic Biosciences Inc (NASDAQ:XBIOGet Rating) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 19,000 shares of the company’s stock, valued at approximately $25,000. Steward Partners Investment Advisory LLC owned approximately 0.14% of Xenetic Biosciences as of its most recent SEC filing. 10.85% of the stock is owned by institutional investors and hedge funds.

About Xenetic Biosciences (NASDAQ:XBIO)

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.

Featured Articles

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.